Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)

NCT04603937 is registered in ClinicalTrials.gov with Kodiak Sciences Inc as lead sponsor.

NCT NCT04603937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04603937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)
Lead sponsor
Kodiak Sciences Inc
Phase
Phase 3
Overall status
Terminated
Start date
September 30, 2020
Completion date
August 31, 2023
Enrollment
459 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema